key: cord-0992190-8tdfxj1p authors: Froes, M. T.; Neves, B. D.; Martins, B.; Silva, M. J. title: Comparison of Multimorbidity in COVID-19 infected and general population in Portugal date: 2020-07-03 journal: nan DOI: 10.1101/2020.07.02.20144378 sha: 46ea2aa46d1ca85a4d79de37c7e79fda4f78d295 doc_id: 992190 cord_uid: 8tdfxj1p Understanding COVID-19 and its risk factors in the Portuguese population is critical to combat this condition. To study the impact of multimorbidity in the population with COVID-19 infection, we performed a descriptive analysis of a dataset extracted from all reported confirmed cases of COVID-19 in Portugal until April 28, 2020. We observed a prevalence of multimorbidity in 4.49% of the 19,598 infected patients. Patients showed an increased risk of hospitalization, ICU admission and mortality with OR 2.70 (CI 95%: 2.52-2.88) for every additional morbidity. Further studies should confirm these findings and special attention should be made on data collection to ensure proper recording of patient comorbidities. In this work, we evaluate the prevalence of multimorbidity and age-adjusted risk of hospitalization, ICU admission and death in the Portuguese population from official data, based on a dataset extracted from SINAVE containing all confirmed cases of COVID-19 in Portugal by April 28, 2020. This retrospective observational study used data provided by DGS after the required institutional and ethical approvals. The sample population consists of all the Portuguese population with SARS-CoV2 confirmed infection as notified by clinicians by April 28, 2020. A broad range of clinical and demographic variables are present in this dataset. In this study we specifically used age, gender, hospital admission, admission in intensive care unit, mortality and patient's underlying conditions. Chronic conditions were provided as a categorical variable on the presence or absence of the following conditions: asthma, malignancy, cardiac disorder (including hypertension), chronic hematological disorder, diabetes, HIV/other immune deficiency, renal disease, liver disease, chronic lung disease, and neuromuscular disorder. We defined multimorbidity as the presence of two or more conditions in the same individual, following the definition used by other authors [6] . Addressed outcomes were hospitalization, admission to ICU unit and reported death. A composite outcome of any of these events was also analyzed. We used Python 3.6 and packages Numpy, Pandas, Seaborn, and SciPy in combination with Microsoft Excel to evaluate and plot the prevalence of multimorbidity. Additionally, IBM SPSS Statistics was used for obtaining age-adjusted risk of hospitalisation, ICU admission and death. Categorical variables were presented as counts and percentages with 95% confidence intervals and comparisons were made using using the χ 2 test. Univariate regression analysis of each individual chronic condition was performed adjusting only for age. A multivariate logistic regression was performed adjusting for age and every other chronic condition with significant statistical association on univariate analysis. Results were considered significant when P <0,05. The overall sample contained 19,598 patient cases, women being more prevalent (58.92%). Among the cases, 16.39% had at least one chronic condition. Diabetes was the most commonly reported condition, reported in 35.59% of the patients with any morbidity. Table 1 shows the reported prevalence of different chronic conditions in the studied population. Multimorbidity, as previously defined, was present in 4.49% of the cases. Figure 1 and Figure 2 plot the prevalence of multimorbidity by age group for the COVID-19 infected general population and hospitalized population, respectively. The prevalence of co-occurring pairs of chronic health conditions, plotted in Figure 4 , shows Diabetes and Neuromuscular disorders as the most common dyad of chronic diseases. 3 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint Figure 5 : Relationship between the observed and expected prevalence of co-occurring pairs of chronic health conditions. All results are given in percentages. The shaded bar depicts the prevalence of each chronic health condition. In the matrix, the first value for each pair is the observed frequency, while the second (italic) is the expected one after multiplying the respective prevalence of each disorder. Chi-square tests were used to determine whether observed frequencies were significantly different from expected frequencies. All p-values were inferior to 5%.) LBP low back pain, HTA hypertension, UBP upper back pain, UI urinary incontinence, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, CHD coronary heart disease, MI previous myocardial infarction, and LC liver cirrhosis of hospitalization. However, only cardiac conditions, diabetes, HIV, chronic kidney disease, and chronic respiratory diseases are associated with more severe cases requiring ICU admission. These results are in line with previous reports where chronic diseases are associated with poorer outcomes [3, 7] . Although the strength of association differs between diseases, every additional morbidity leads to an increased risk of the composite outcome of hospitalization, ICU admission and mortality. Multimorbidity was previously studied in the general Portuguese population in 2014 by Laires et al., using data from the fifth National Health Interview Survey (Inquérito Nacional de Saúde, INS) [6] . Prevalence of multimorbidity on the Laires at al. study can be compared with our data. Although only individuals aged 25-79 were included in that study, this constitutes a robust sample for morbidity prevalence in Portugal. We can observe in Figure 1 to Figure 3 a rise in chronic health conditions with increasing age as expected. However, multimorbidity is much less prevalent in our study population (4.49% vs 43.9%). Since the beginning of this pandemic there has been significant public awareness regarding the higher risk of older people with comorbidities. This may have induced efforts to protect and isolate this population. The findings of this study could thus confirm the positive effect of such measures, given the younger and healthier population in the COVID-19 dataset. The discrepancy may however be related to different reporting methods. For instance, the maximum number of reported simultaneous morbidities in the COVID-19 infected population was only 5 disorders, which is half of the maximum number of morbidities found in the INS population (10 disorders). Since the total number of conditions between both datasets is not so different (COVID-19: 10 diseases; INS: 13 diseases), a possible explanation for the higher number of co-occurring conditions in the INS population can be the combination of self-diagnoses with the presence of more "subjective" disorders such as: lower and upper back pain, allergies, depression, and urinary incontinence. This study has several limitations. First of all, the cross-sectional nature of the COVID-19 dataset makes it impossible to account for incomplete outcomes, since several patients could ultimately be hospitalized or die after the end of observation. Reported data on outcomes may therefore be underestimated, so careful interpretation is advised until more data is available. More importantly, despite the fact that no standard set of conditions is established to define multimorbidity, chronic conditions were given on broad groups and there is no specific information on individual conditions. For example, diabetes is given as one group and no distinction is made between type 1 and type 2 diabetes. Therefore, measured morbidities may herald heterogeneous groups of diseases with different degrees of severity, which may influence outcomes. Future datasets should include more accurate information on chronic conditions Another important concern is related to the risk of under-reporting in this dataset, which becomes obvious by analyzing reported cardiac diseases. Given that cardiovascular diseases, particularly hypertension, are very prevalent in the Portuguese population [8] , the observed prevalence of 0.28% in our study highly suggests that under-reporting may have occurred. We could notice that, surprisingly, cardiovascular diseases are absent from the available list of previous conditions in SINAVE's reporting page, as seen in Figure 6b , which could have contributed to a lower notification of this comorbidity. 5 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint Although we acknowledge that this dataset was not primarily designed for research, but rather for public health proceedings and government information, we believe that a better user interface design and a more rational set of chronic conditions could effortlessly improve the quality of recorded data. One important lesson we can learn from this pandemic is the important contribution that quickly gathered relevant clinical data and health information systems, such as SINAVE, can have in this setting. Overall, we consider SINAVE to be very susceptible to under-reporting, specially regarding multimorbidity. This is due to a confusing and non-practical interface that allows doctors to skip filling some important fields in the entry form. Some suggestions to improve future studies regarding multimorbidity, using SINAVE's data, are: • Redesign the reporting form, making data entry more effective and faster. The current user interface could be simplified, while encouraging the input of relevant comorbidity information; • Integrate SINAVE data with the patient's health record or with data from the new Trace Covid-19 system, to provide richer data relevant to COVID-19. This could be a way of implementing the redesigned user interface suggested above; • Make it mandatory to input if comorbidities are absent; if present, the filling of the entry form inputs related to comorbidities and the specific chronic conditions should be mandatory. As seen in Figure 6 , the list of comorbidities only becomes visible if a previous parameter is filled; • Make the entry of all known chronic conditions by healthcare professionals more persuasive; • Add cardiovascular diseases to the list of comorbidities. To conclude, findings in our study show that multimorbidity is significantly associated with poor outcomes in COVID-19 infection. Further data is needed to inform about the strength of this association and about the significance of observed differences in multimorbidity prevalence between infected patients and the general population of Portugal. We believe that data collection problems may have occurred and influenced outcome measurement. We also provide recommendations for improving the data collection user interface that could improve quality of health information about the COVID-19 infected population, while increasing confidence in SINAVE data. 6 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint 10 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 3, 2020. . https://doi.org/10.1101/2020.07.02.20144378 doi: medRxiv preprint Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Antonio Pesenti, and COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region Age-adjusted associations between comorbidity and outcomes of COVID-19: a review of the evidence. medRxiv DGS The current and projected burden of multimorbidity: a cross-sectional study in a Southern Europe population Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease Prevalence, awareness, treatment and control of hypertension and salt intake in Portugal: changes over a decade. The PHYSA study